{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000006","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.882366+00:00","generated_at":"2026-06-04T13:44:58.055865+00:00","sec_items":["1.01","1.02","2.03","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AEON Biopharma secures $15M convertible note from Daewoong and aligns with FDA on Phase 3 migraine trial design","bullets":["Issues up to $15M senior secured convertible notes to Daewoong; first $5M tranche closes within 10 days, second $10M subject to license amendment.","Terminates forward purchase agreements with ACM and Polar; retains ~3.1M shares each, up to $1.5M liquidated damages for registration failures.","FDA confirms primary endpoint (change in mean monthly migraine days over weeks 13-24) for Phase 3 episodic and chronic migraine programs.","Interim analysis of ongoing Phase 2 chronic migraine study now planned; data expected Q2 2024, complete top-line data on track for Q3 2024.","ABP-450 Phase 2 chronic migraine study enrolled 492 patients; will use patented injection paradigm with fewer injections than current treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000006","json":"https://secwatch.observer/filing/0001837607-24-000006.json","markdown":"https://secwatch.observer/filing/0001837607-24-000006.md","text":"https://secwatch.observer/filing/0001837607-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/0001837607-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/aeon-20240318x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:44:58.055865+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"537c038ef86498ebb4dbb9ae3063550065c60b94","claim":"AEON Biopharma, Inc. incurred convertible notes of $15.0 million with Daewoong Pharmaceutical Co., LTD. at 15.79% maturing three years from the funding date.","evidence_excerpt":"On March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “Convertible Note” and together, the “Convertible Notes”) in the principal amount of up to $15.0 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/0001837607-24-000006-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$15.0 million"},{"label":"Counterparty","value":"Daewoong Pharmaceutical Co., LTD."},{"label":"Rate","value":"15.79%"},{"label":"Maturity","value":"three years from the funding date"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"41a1081e7da029ca2d46d2e5b9eea5193494b415","claim":"AEON Biopharma, Inc. entered into Subscription Agreement with Daewoong Pharmaceutical Co., LTD. valued at $15.0 million (effective 2024-03-19).","evidence_excerpt":"On March 19, 2024, AEON Biopharma, Inc. (“AEON” or the “Company”) and AEON Biopharma Sub, Inc., a subsidiary of the Company (“AEON Sub”), entered into a subscription agreement (the “Subscription Agreement”) with Daewoong Pharmaceutical Co., LTD. (“Daewoong”) relating to the sale and issuance by the Company of senior secured convertible notes (each, a “Convertible Note” and together, the “Convertible Notes”) in the principal amount of up to $15.0 million","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000006/0001837607-24-000006-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Daewoong Pharmaceutical Co., LTD."},{"label":"Value","value":"$15.0 million"},{"label":"Effective","value":"2024-03-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}